

Technické aspekty odběru a hodnocení biopsií prostaty u mužů s podezřením na včasný karcinom prostaty – druhá část

BARNABY CHAPPELL a JOHN McLOUGHLIN

Department of Urology, West Suffolk Hospital, Bury St Edmunds, Suffolk, UK

LITERATURA

- 1 Egevad L, Norlen BJ, Norberg M. The value of multiple core biopsies for predicting the Gleason score of prostate cancer. *BJU Int* 2001; **88**: 716–21
- 2 Makhlof AA, Krupski TL, Kunkle D, Theodorescu D. The effect of sampling more cores on the predictive accuracy of pathological grade and tumour distribution in the prostate biopsy. *BJU Int* 2004; **93**: 271–4
- 3 Montironi R, Mazzucchelli R, Scarpelli M. Precancerous lesions and conditions of the prostate: from morphological and biological characterization to chemoprevention. *Ann NY Acad Sci* 2002; **963**: 169–84
- 4 San Francisco IF, Olumi AF, Kao J, Rosen S, DeWolf WC. Clinical management of prostatic intraepithelial neoplasia as diagnosed by extended needle biopsies. *BJU Int* 2003; **91**: 350–4
- 5 Green JS, Knight RJ, Hunter-Campbell P *et al.* An investigation into the spatial relationship between prostate intraepithelial neoplasia and cancer. *Prostate Cancer Prostatic Dis* 2001; **4**: 97–100
- 6 Prange W, Erbersdobler A, Hammerer P *et al.* Significance of high-grade prostatic intraepithelial neoplasia in needle biopsy specimens. *Urology* 2001; **57**: 486–90
- 7 Davidson D, Bostwick DG, Qian J *et al.* Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. *J Urol* 1995; **154**: 1295–9
- 8 Chan TY, Chan DY, Stutzman KL, Epstein JI. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? *J Urol* 2001; **166**: 2181–4
- 9 Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. *J Urol* 1994; **151**: 1571–4
- 10 Stephan C, Jung K, Diamandis EP, Rittenhouse HG, Lein M, Loening SA. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. *Urology* 2002; **59**: 2–8
- 11 Raviv G, Zlotta AR, Janssen T *et al.* Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma? *Cancer* 1996; **77**: 2103–8
- 12 Wiley EL, Davidson P, McIntire DD, Sagalowsky AI. Risk of concurrent prostate cancer in cystoprostatectomy specimens is related to Volume of highgrade prostatic intraepithelial neoplasia. *Urology* 1997; **49**: 692–6
- 13 Kronz JD, Allan CH, Shaikh AA, Epstein JI. Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. *Am J Surg Pathol* 2001; **25**: 1079–85
- 14 Naya Y, Ayala AG, Tamboli P, Babaian RJ. Can the number of cores with highgrade prostate intraepithelial neoplasia predict cancer in men who undergo repeat biopsy? *Urology* 2004; **63**: 503–8
- 15 Iczkowski KA, Chen HM, Yang XJ, Beach RA. Prostate cancer diagnosed after initial biopsy with atypical small acinar proliferation suspicious for malignancy is similar to cancer found on initial biopsy. *Urology* 2002; **60**: 851–4
- 16 Chan TY, Epstein JI. Follow-up of atypical prostate needle biopsies suspicious for cancer. *Urology* 1999; **53**: 351–5
- 17 Mian BM, Naya Y, Okihara K, Vakar-Lopez F, Troncoso P, Babaian RJ. Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multi-site biopsy. *Urology* 2002; **60**: 836–40
- 18 D'Amico AV, Whittington R, Malkowicz SB *et al.* Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer. *Prostate Cancer Prostatic Dis* 2000; **3**: 259–64
- 19 Freedland SJ, Aronson WJ, Csathy GS *et al.* Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA

- recurrence after radical prostatectomy: results from the SEARCH database. *Urology* 2003; **61**: 742-7
- 20 Grossklaus DJ, Coffey CS, Shappell SB, Jack GS, Chang SS, Cookson MS. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. *J Urol* 2002; **167**: 2032-5
- 21 Iczkowski KA, Casella G, Seppala RJ *et al*. Needle core length in sextant biopsy influences prostate cancer detection rate. *Urology* 2002; **59**: 698-703
- 22 Hoedemaeker RF, Van der Kwast TH, Schroder FH. The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy. *BJU Int* 2003; **92** (Suppl. 2): 92-6
- 23 Wills ML, Sauvageot J, Partin AW, Gurganus R, Epstein JI. Ability of sextant biopsies to predict radical prostatectomy stage. *Urology* 1998; **51**: 759-64
- 24 Tombal B, Tajeddine N, Cosyns JP *et al*. Does site-specific labelling and individual processing of sextant biopsies improve the accuracy of prostate biopsy in predicting pathological stage in patients with T1c prostate cancer? *BJU Int* 2002; **89**: 543-8
- 25 Miyake H, Sakai I, Ishimura T, Hara I, Eto H. Significance of cancer detection in the anterior lateral horn on systematic prostate biopsy: the effect on pathological findings of radical prostatectomy specimens. *BJU Int* 2004; **93**: 57-9
- 26 Badalament RA, Miller MC, Peller PA *et al*. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. *J Urol* 1996; **156**: 1375-80
- 27 de la Taille A, Katz A, Bagiella E, Olsson CA, O'Toole KM, Rubin MA. Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage. *Urology* 1999; **54**: 1039-43
- 28 Wymenga LF, Duisterwinkel FJ, Groenier K, Mensink HJ. Ultrasoundguided seminal vesicle biopsies in prostate cancer. *Prostate Cancer Prostatic Dis* 2000; **3**: 100-6
- 29 Van der Kwast TH, Lopes C, Martikainen PM *et al*. Report of the Pathology Committee: false-positive and falsenegative diagnoses of prostate cancer. *BJU Int* 2003; **92** (Suppl. 2): 62-5
- 30 O'Dowd GJ, Miller MC, Orozco R, Veltri RW. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. *Urology* 2000; **55**: 553-9
- 31 Djavan B, Remzi M, Marberger M. When to biopsy and when to stop biopsying. *Urol Clin North Am* 2003; **30**: 253-62
- 32 Bill-Axelsson A, Holmberg L, Norlen B, Busch C, Norberg M. No increased prostate cancer incidence after negative transrectal ultrasound guided multiple biopsies in men with increased prostate specific antigen and/or abnormal digital rectal examination. *J Urol* 2003; **170**: 1180-3
- 33 Hayek OR, Noble CB, de la Taille A, Bagiella E, Benson MC. The necessity of a second prostate biopsy cannot be predicted by PSA or PSA derivatives (density or free: total ratio) in men with prior negative prostatic biopsies. *Curr Opin Urol* 1999; **9**: 371-5
- 34 Boddy JL, Pike DJ, Malone PR. A sevenyear follow-up of men following a benign prostate biopsy. *Eur Urol* 2003; **44**: 17-20
- 35 Djavan B. Editorial comment. *Urology* 2000; **55**: 559
- 36 Remzi M, Djavan B, Wammack R *et al*. Can total and transition zone Volume of the prostate determine whether to perform a repeat biopsy? *Urology* 2003; **61**: 161-6
- 37 Lopez-Corona E, Ohori M, Scardino PT, Reuter VE, Gonen M, Kattan MW. A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. *J Urol* 2003; **170**: 1184-8
- 38 Aus G, Abbou CC, Pacik D *et al*. EAU guidelines on prostate cancer. *Eur Urol* 2001; **40**: 97-101
- 39 Rietbergen JB, Hoedemaeker RF, Kruger AE, Kirkels WJ, Schroder FH. The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. *J Urol* 1999; **161**: 1192-8
- 40 Weinstein MH, Epstein JI. Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy. *Hum Pathol* 1993; **24**: 624-9
- 41 Shepherd D, Keetch DW, Humphrey PA, Smith DS, Stahl D. Repeat biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy. *J Urol* 1996; **156**: 460-2
- 42 Goeman L, Joniau S, Ponette D *et al*. Is low-grade prostatic intraepithelial neoplasia a risk factor for cancer? *Prostate Cancer Prostatic Dis* 2003; **6**: 305-10
- 43 Rietbergen JB, Kruger AE, Hoedemaeker RF, Bangma CH, Kirkels WJ, Schroder FH. Repeat screening for prostate cancer after 1-year followup in 984 biopsied men. clinical and pathological features of detected cancer. *J Urol* 1998; **160**: 2121-5
- 44 Noguchi M, Yahara J, Koga H, Nakashima O, Noda S. Necessity of repeat biopsies in men for suspected prostate cancer. *Int J Urol* 1999; **6**: 7-12

- 45 **Gore JL, Shariat SF, Miles BJ et al.** Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. *J Urol* 2001; **165**: 1554–9
- 46 **Norberg M, Egevad L, Holmberg L, Sparen P, Norlen BJ, Busch C.** The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. *Urology* 1997; **50**: 562–6
- 47 **Langer JE, Rovner ES, Coleman BG et al.** Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy. *J Urol* 1996; **155**: 228–31
- 48 **Bozlu M, Ulusoy E, Doruk E et al.** Voiding impairment after prostate biopsy: does tamsulosin treatment before biopsy decrease this morbidity? *Urology* 2003; **62**: 1050–3
- 49 **Park S, Shinohara K, Grossfeld GD, Carroll PR.** Prostate cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy. *J Urol* 2001; **165**: 1409–14
- 50 **Lui PD, Terris MK, McNeal JE, Stamey TA.** Indications for ultrasound guided transition zone biopsies in the detection of prostate cancer. *J Urol* 1995; **153**: 1000–3
- 51 **Fink KG, Hutarew G, Esterbauer B et al.** Evaluation of transition zone and lateral sextant biopsies for prostate cancer detection after initial sextant biopsy. *Urology* 2003; **61**: 748–53
- 52 **Chen ME, Troncso P, Johnston DA, Tang K, Babaian RJ.** Optimization of prostate biopsy strategy using computer based analysis. *J Urol* 1997; **158**: 2168–75
- 53 **Stewart CS, Leibovich BC, Weaver AL, Lieber MM.** Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. *J Urol* 2001; **166**: 86–91
- 54 **Patel AR, Jones JS, Rabets J, DeOreo G, Zippe CD.** Parasagittal biopsies add minimal information in repeat saturation prostate biopsy. *Urology* 2004; **63**: 87–9
- 55 **Aus G, Abbou CC, Pacik D et al.** *Guidelines on Prostate Cancer*. European Association of Urology; 2003
- 56 **Lefkowitz GK, Sidhu GS, Torre P, Lepor H, Taneja SS.** Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling? *Urology* 2001; **58**: 999–1003
- 57 **Zackrisson B, Aus G, Bergdahl S et al.** The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. *J Urol* 2004; **171**: 1500–3
- 58 **Roehl KA, Antenor JA, Catalona WJ.** Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6–4.0 ng/mL range. *J Urol* 2002; **168**: 922–5

Korespondence:

John McLoughlin,
Department of Urology,
West Suffolk Hospital,
Bury St Edmunds,
Suffolk IP33 2QZ, UK.
e-mail:

John.Mcloughlin@wsh.nhs.uk

Zkratky:

(f, t, f/t) PSA, (free, total, free/ total) PSA; TRUS-B, TRUS-guided biopsy; PPV, positive predictive value; RP, radical prostatectomy; PSAD, PSA density; TZ, transition zone; PZ, peripheral zone; LG/HGPIN, low-, high-grade prostatic intraepithelial neoplasia.